BridgeBio Oncology Therapeutics, Inc. Logo

BridgeBio Oncology Therapeutics, Inc.

Clinical-stage biopharma developing inhibitors for genetically driven cancers.

BBOT | US

Overview

Corporate Details

ISIN(s):
KYG4444H1011
LEI:
Country:
United States of America
Address:
256 E. GRAND AVENUE, SUITE 104, 94080 SOUTH SAN FRANCISCO

Description

BridgeBio Oncology Therapeutics, Inc. (BBOT) is a clinical-stage biopharmaceutical company focused on precision oncology. The company develops a pipeline of novel, bioavailable small molecule inhibitors designed to treat patients with RAS-dependent cancers and other malignancies with clear genetic drivers. Its core strategy centers on inhibiting active RAS, aiming to create transformative medicines that advance beyond current therapeutic approaches. BBOT was launched to accelerate the development of its parent company's precision oncology portfolio.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2024-12-15
English
4.2 MB
2024-10-30
German
1.8 MB
2024-08-14
French
0.5 MB
2024-05-22
English
2.1 MB
2024-03-10
English
3.5 MB
2024-01-15
German
1.2 MB
2023-11-20
English
5.1 MB

Full Filing History Restricted

Access to specific historical documents or filtered results is limited in the Web UI. Request access to the complete dataset.

Automate Your Workflow. Get a real-time feed of all BridgeBio Oncology Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BridgeBio Oncology Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BridgeBio Oncology Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Develops drug delivery technology for localized chemotherapy in solid tumors.
Virgin Islands (British)
CRTX
CRISPR Therapeutics AG Logo
A gene-editing company developing gene-based medicines for serious diseases.
United States of America
CRSP
Crossject Logo
Develops emergency medications delivered via a needle-free auto-injector platform.
France
ALCJ
CSL Ltd. Logo
Global biotechnology company developing biotherapies, vaccines, and specialty medicines.
Australia
CSL
CS Medica A/S Logo
Develops and manufactures OTC medical devices and cosmetics containing cannabidiol.
Denmark
CSMED
CTC BIO, INC. Logo
Develops and manufactures human and animal health products using microbial fermentation.
South Korea
060590
Cue Biopharma, Inc. Logo
Develops biologics to selectively modulate the immune system for cancer and autoimmune diseases.
United States of America
CUE
Cullinan Therapeutics, Inc. Logo
A clinical-stage biopharmaceutical company developing therapies for cancer and autoimmune diseases.
United States of America
CGEM
CUMBERLAND PHARMACEUTICALS INC Logo
Acquires, develops, and commercializes branded drugs for hospital and acute care.
United States of America
CPIX
Cuorips Inc. Logo
Develops iPS cell-derived therapies and provides cell processing contract services.
Japan
4894

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.